ArticleJournal of medical biochemistry2026
Prognostic value of circulating neuron-specific enolase combined with erythrocyte and platelet distribution indices in patients with severe traumatic brain injury.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe traumatic brain injury (STBI) is associated with high mortality and long-term neurological disability. Early identification of reliable circulating biomarkers may improve prognostic stratification and clinical management. Haematological distribution indices, including red cell distribution width (RDW) and platelet distribution width (PDW), along with neuron-specific enolase (NSE), reflect systemic inflammation, platelet activation, and neuronal injury following traumatic brain injury. However, their combined prognostic value in STBI remains incompletely understood. Methods: A retrospective study was conducted, including 96 consecutive patients with STBI admitted between March 2020 and March 2023. The GCS score used for rSIG calculation was the first documented admission score before definitive neurosurgical treatment. Treatment was individualised according to injury severity and imaging findings, including conservative management, hematoma evacuation, decompressive craniectomy, ventilatory support, and intensive care when indicated. Peripheral blood levels of RDW, PDW, and serum NSE were measured at admission using automated haematology analysis and enzyme-linked immunosorbent assay. According to the Glasgow Outcome Scale (GOS), evaluated 3 months after injury, patients were classified into a good-prognosis group (n= 46) and a poor-prognosis group (n = 50).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.